J 2021

Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18–30 Years Old): An Independent Post-Marketing Study

RIAD, Abanoub, Andrea POKORNÁ, Jitka KLUGAROVÁ, Natália ANTALOVÁ, Lucia KANTOROVÁ et. al.

Základní údaje

Originální název

Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18–30 Years Old): An Independent Post-Marketing Study

Autoři

RIAD, Abanoub (818 Egypt, garant, domácí), Andrea POKORNÁ (203 Česká republika, domácí), Jitka KLUGAROVÁ (203 Česká republika, domácí), Natália ANTALOVÁ (703 Slovensko, domácí), Lucia KANTOROVÁ (703 Slovensko, domácí), Michal KOŠČÍK (203 Česká republika, domácí) a Miloslav KLUGAR (203 Česká republika, domácí)

Vydání

Pharmaceuticals, Basel, MDPI, 2021, 1424-8247

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.215

Kód RIV

RIV/00216224:14110/21:00122615

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000715120800001

Klíčová slova anglicky

BNT162 vaccine; COVID-19; Czech Republic; drug-related side effects and adverse reactions; mass vaccination; mRNA-1273 vaccine; phase IV; prevalence; young adult

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 7. 12. 2021 13:12, Mgr. Tereza Miškechová

Anotace

V originále

Young adults had been widely perceived as a low-risk group for COVID-19 severity; therefore, they were deprioritised within the mass vaccination strategies as their prognosis of COVID-19 infection is relatively more favourable than older age groups. On the other hand, vaccination of this demographic group is indispensable to achieve herd immunity. A cross-sectional survey-based study was used to evaluate the side effects of mRNA-based COVID-19 vaccines among university students in the Czech Republic. The validated questionnaire was delivered in a digital form, and it consisted of demographic data; COVID-19 vaccine-related anamnesis; and local, systemic, orofacial, and skin-related side effects’ prevalence, onset, and duration. Out of the 539 included participants, 70.1% were females and 45.8% were <23 years old. The vast majority (95.2%) reported at least one side effect. The most common side effect was injection site pain (91.8%), followed by fatigue (62.5%), headache (36.4%), and muscle pain (34.9%). The majority of local side effects occurred after both doses (74.4%), while most systemic side effects occurred after the second dose only (56.2%). Most local (94.2%) and systemic (93.3%) side effects resolved within three days after vaccination. Females participants’ adjusted odds ratio (AOR) showed they were 2.566 (CI 95%: 1.103–5.970) times more likely to experience post-vaccination side effects, and the participants who received two doses reported an increased AOR of 1.896 (0.708–5.077) for experiencing side effects. The results of this study imply that mRNA-based COVID-19 vaccines are highly probably safe for young adults, and further studies are required to investigate the role of medical anamnesis, prior COVID-19 infection, and gender in side effects incidence.

Návaznosti

LTC20031, projekt VaV
Název: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST
MUNI/A/1608/2020, interní kód MU
Název: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III
Investor: Masarykova univerzita, Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III
MUNI/IGA/1068/2020, interní kód MU
Název: Methodological and practical aspects of the development of guidelines and rapid guidelines in public health (Akronym: RAPguidelines-public-health)
Investor: Masarykova univerzita, Methodological and practical aspects of the development of guidelines and rapid guidelines in public health
MUNI/IGA/1543/2020, interní kód MU
Název: Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic (Akronym: Evidence-Based Practice in Czechia)
Investor: Masarykova univerzita, Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic